## Cell-free DNA (cfDNA) workflow for the risk definition of dose-limiting and recurrent neutropenia in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC)

<sup>1</sup> Department of Medicine (DAME), University of Udine, UD, Italy. <sup>2</sup> Department of Medical Oncologico (CRO), IRCCS, Aviano, PN, Italy. <sup>3</sup> Clinical and Experimental Pharmacology, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN, Italy.<sup>4</sup> Department of Medical Oncology, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) Udine, UD, Italy.<sup>5</sup> Institute of Human Genetics, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC) Udine, UD, Italy.<sup>6</sup> Molecular Oncology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, PN, Italy

## Background


- We previously observed the differential dinamics of cfDNA during treatment with CDK4/6i in hormone receptor (HR)positive/HER2- negative MBC (luminal MBC).
- We now hypothesize a potential association between leucocytes and medium/long cfDNA fractions (mainly deriving from citolysis).
- Aim of the study was to evaluate the feasibility of a cfDNAbased workflow as a novel tool for assessing the risk of treatment-induced recurrent-neutropenia (rec-NP) and NPinduced CDK4/6i dose reduction (DR) in patients (pts) treated for luminal MBC.

## Methods

- 83 luminal MBC patients (pts) treated with first line ET and CDK4/6i
- cfDNA was characterized through droplet digital PCR (ddPCR) based on different ACTB DNA fragments lengths: short (s), medium (sl) and long (l).
- Blood samples were collected at baseline (BL) and after 3 months (E1).
- Associations between clinical characteristics, cfDNA, rec-NP (≥3) NP events) and DR were explored through Kruskal Wallis

Palmero L<sup>1,2</sup>, Mazzeo R<sup>1,2</sup>, Buriolla S<sup>1,4</sup>, Allegri L<sup>5</sup>, Bortot L<sup>1,4</sup>, Franzoni A<sup>5</sup>, Michelotti A<sup>1,2</sup>, Stefani EC<sup>1</sup>, Turra G<sup>1</sup>, Zilli M<sup>1</sup>, Di Nardo P<sup>2</sup>, Roncato R<sup>3</sup>, Bonotto M<sup>4</sup>, Cecchin E<sup>3</sup>, Belletti B<sup>6</sup>, Toffoli G<sup>3</sup>, Baldassarre G<sup>6</sup>, Damante G<sup>1,5</sup> Gerratana L<sup>1,2</sup>, Puglisi F<sup>1,2</sup>

rec-NP



Correspondence to: lorenza.palmero@cro.it

rec-NP

rec-NP





Results		
ble 1. Variables tested and DR.		
Variables tested	Ρ	
e novo metastatic (lower risk)	0.0304	
High ACTB_sl BL	0.0096	

ble 2. Pts and NG3-G4.	
N°pts	83
NG3-G4	46 (55%)
Rec-NP	29 (35%)
ose Reduction after NG3-G4	12 (26%)

ble 3. Variables tested not significant.		
ACTB_sl and Rec-NP	> 0.05	
Low WBC BL and DR	> 0.05	
Low N BL and DR	> 0.05	
Low LDH and DR	> 0.05	
Liver met and DR	> 0.05	
Bone met and DR	> 0.05	

Study sponsored by Ricerca Finalizzata Italian Ministry of Health and LILT